L20-L30
Conditions
Interventions
Group 1: A Patient Survey is conducted using the following patient questionnaires: (PROs):
o Patient Oriented Eczema Measurement (POEM)
o Disease Control Questionnaire
o Worst Pruritus Numerical Rat
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: • physician confirmed diagnosis of atopic dermatitis • moderate to severe AD patients who are (i) current candidates for systemic therapy for AD according to the HCP, or (ii) currently receiving systemic therapy for AD. • medication history available within the last 6 months • able to understand the questionnaires, with parental support as required for adolescents • willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable
Exclusion criteria
Exclusion criteria: Patients will be excluded if currently participating in interventional clinical trial(s). Participation in another non-interventional study or registry does not exclude a patient from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterize the multidimensional burden of disease in adolescent and adult patients with moderate to severe AD with single data collection | — |
Secondary
| Measure | Time frame |
|---|---|
| • To describe the patient characteristics, current local treatment patterns and the treatment history of moderate to severe AD patients in dermatology offices and clinics. • To characterize disease burden related to pain, sleep and mental health in patients with moderate to severe AD. • To evaluate work productivity and out of pocket costs for AD patients • To characterize health care resource utilization. • To assess the impact of chronic comorbidities on disease burden. • To evaluate the frequency and characteristics of patients with inadequately controlled disease receiving different treatments. • To evaluate the frequency and characteristics of patients who experience AD flare. | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Kuwait, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Saudi Arabia, Slovakia, Spain, Switzerland, Taiwan, Turkey, United Arab Emirates
Contacts
Public ContactStephanie Hagl
AbbVie Deutschland GmbH & Co. KG
Outcome results
None listed